全文获取类型
收费全文 | 83445篇 |
免费 | 8204篇 |
国内免费 | 164篇 |
专业分类
耳鼻咽喉 | 1185篇 |
儿科学 | 2518篇 |
妇产科学 | 1791篇 |
基础医学 | 11915篇 |
口腔科学 | 2040篇 |
临床医学 | 10211篇 |
内科学 | 14722篇 |
皮肤病学 | 1334篇 |
神经病学 | 6754篇 |
特种医学 | 2899篇 |
外国民族医学 | 11篇 |
外科学 | 11462篇 |
综合类 | 1698篇 |
一般理论 | 67篇 |
预防医学 | 9522篇 |
眼科学 | 1855篇 |
药学 | 6788篇 |
1篇 | |
中国医学 | 78篇 |
肿瘤学 | 4962篇 |
出版年
2021年 | 1113篇 |
2020年 | 741篇 |
2019年 | 1125篇 |
2018年 | 1399篇 |
2017年 | 1013篇 |
2016年 | 1102篇 |
2015年 | 1260篇 |
2014年 | 1642篇 |
2013年 | 2589篇 |
2012年 | 3484篇 |
2011年 | 3764篇 |
2010年 | 2010篇 |
2009年 | 1947篇 |
2008年 | 3246篇 |
2007年 | 3554篇 |
2006年 | 3425篇 |
2005年 | 3486篇 |
2004年 | 3276篇 |
2003年 | 3033篇 |
2002年 | 2961篇 |
2001年 | 2718篇 |
2000年 | 2830篇 |
1999年 | 2519篇 |
1998年 | 1113篇 |
1997年 | 933篇 |
1996年 | 914篇 |
1995年 | 815篇 |
1994年 | 840篇 |
1993年 | 768篇 |
1992年 | 2099篇 |
1991年 | 2029篇 |
1990年 | 1909篇 |
1989年 | 1869篇 |
1988年 | 1784篇 |
1987年 | 1796篇 |
1986年 | 1699篇 |
1985年 | 1669篇 |
1984年 | 1388篇 |
1983年 | 1262篇 |
1982年 | 853篇 |
1981年 | 716篇 |
1980年 | 642篇 |
1979年 | 1216篇 |
1978年 | 875篇 |
1977年 | 764篇 |
1976年 | 720篇 |
1975年 | 715篇 |
1974年 | 859篇 |
1973年 | 753篇 |
1972年 | 733篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Mark Ehlers Marc Bjurlin John Gore Raj Pruthi Gopal Narang Ray Tan Matthew Nielsen Anqi Zhu Allison Deal Angela Smith 《Urologic oncology》2021,39(1):76.e1-76.e7
ObjectiveFinancial toxicity (FT) has been defined as the patient-level impact of the costs of cancer care. Our objective was to better characterize FT among bladder cancer patients as well as oncologic, demographic and insurance characteristics related to FT.MethodsWe conducted a cross-sectional survey of the Bladder Cancer Advocacy Network Patient Survey Network using the validated COST (COmprehensive Score for financial Toxicity) questionnaire. Our primary outcome was relative degree of FT, with lower COST scores corresponding to worse FT. Wilcoxon rank sum tests and multiple regression were used to evaluate differences in demographic, diagnostic and treatment characteristics as they related to degree of FT.ResultsAmong 226 patients, median age was 68 years with 64% male, 83% married, and 49% with Medicare with supplemental insurance. Respondents reported an average of 65 months since diagnosis, with 62% reporting noninvasive disease. Mean COST was 28.4 (range 0–44). On multivariable analysis, patients who were younger, with a household annual income less than $50,000, not retired, or with insurance that was neither Medicare nor employer paid were significantly more likely to have worse FT. A majority of respondents (63.5%) agreed or strongly agreed that they would be interested in discussing cost in the context of their treatment preferences, independent of COST score (P = 0.24).ConclusionsA national cross-sectional survey demonstrated high prevalence of FT which was worse among younger patients with lower incomes, not retired, and without employer-paid or Medicare insurance. Most patients preferred to discuss treatment costs with their bladder cancer provider. 相似文献
992.
993.
994.
995.
Dean W. Smith 《Hand (New York, N.Y.)》2021,16(1):NP1
Background: An unusual case involving a middle-aged male with a 9-year history of presumptive chronic regional pain syndrome (CRPS) and ulnar neuropathy was referred for failure in treatment. Methods: On presentation, the patient was requesting an amputation of his arm. However, work-up uncovered a periosteal extra-digital glomus tumor on the base of the small finger metacarpal. Results: Surgical excision of the lesion resulted in rapid resolution of his pain and normal hand function was ultimately restored. Conclusions: Glomus tumors account for up to 5% of all soft tissue tumors of the upper extremity, occurring most frequently within or adjacent to the nail bed. Time from onset of symptoms to correct diagnosis may not be established for many years, especially with atypical tumor locations. Although glomus tumors have been widely reported, atypical locations of these tumors should be included in the differential diagnosis for patients with unusual chronic pain or neuropathy. Furthermore, when evaluating a chronic pain patient, our findings support the opinion that assignment of the diagnosis of CRPS should only be a diagnosis of exclusion. 相似文献
996.
BackgroundRate of change in lung function is used as a measure of disease progression and a predictor of mortality in individuals with cystic fibrosis (CF). The aim of this study was to determine the national rate of decline in percent predicted Forced Expiratory Volume in 1 second (ppFEV1) in adults in the UK accounting for age, sex and pancreatic status.MethodsData on ppFEV1 for adults with CF, excluding those post lung transplantation, was extracted from the UK CF registry between 2015 and 2017. Multilevel modelling was conducted to calculate the annual rate of change in ppFEV1 accounting for age, sex and pancreatic status.ResultsOverall annual ppFEV1 decline was -1.52% (95% CI: -1.66 to -1.38%) and -0.55% (95% CI: -0.86 to -0.23%) in pancreatic insufficient (PI) and sufficient (PS) adults respectively. In PI individuals, females had a greater rate of decline in ppFEV1. There were differences between age groups. The fastest rate of decline was observed in the 18–28 years group, declining -1.76% (95% CI: -2.06 to -1.46) and -1.61% (95% CI: -1.91 to -1.31) per year in PI females and males respectively. The pattern between the sexes and age categories was more inconsistent in the PS group.ConclusionsThe average annual rates of decline in lung function in adults with CF in the UK are similar to reports from other large international cohorts. Pancreatic status has a marked impact on average rate of decline. Younger adults, especially females, have a faster rate of decline and need close monitoring. 相似文献
997.
Charles Varnell Jr Lyndsay A. Harshman Laurie Smith Chunyan Liu Shiran Chen Samhar Al-Akash Gina-Marie Barletta Craig Belsha Paul Brakeman Abanti Chaudhuri Paul Fadakar Rouba Garro Caroline Gluck Jens Goebel David Kershaw Debora Matossian Corina Nailescu Hiren P. Patel Cozumel Pruette Saritha Ranabothu Nancy Rodig Jodi Smith Judith Sebestyen VanSickle Patricia Weng Lara Danziger-Isakov David K. Hooper Michael Seifert 《American journal of transplantation》2021,21(8):2740-2748
There are limited data on the impact of COVID-19 in children with a kidney transplant (KT). We conducted a prospective cohort study through the Improving Renal Outcomes Collaborative (IROC) to collect clinical outcome data about COVID-19 in pediatric KT patients. Twenty-two IROC centers that care for 2732 patients submitted testing and outcomes data for 281 patients tested for SARS-CoV-2 by PCR. Testing indications included symptoms and/or potential exposures to COVID-19 (N = 134, 47.7%) and/or testing per hospital policy (N = 154, 54.8%). Overall, 24 (8.5%) patients tested positive, of which 15 (63%) were symptomatic. Of the COVID-19-positive patients, 16 were managed as outpatients, six received non-ICU inpatient care and two were admitted to the ICU. There were no episodes of respiratory failure, allograft loss, or death associated with COVID-19. To estimate incidence, subanalysis was performed for 13 centers that care for 1686 patients that submitted all negative and positive COVID-19 results. Of the 229 tested patients at these 13 centers, 10 (5 asymptomatic) patients tested positive, yielding an overall incidence of 0.6% and an incidence among tested patients of 4.4%. Pediatric KT patients in the United States had a low estimated incidence of COVID-19 disease and excellent short-term outcomes. 相似文献
998.
Abdullah Al-Mitwalli Grigorios Kyriazis Omar El-Taji Elizabeth Chandra Wearmouth Deborah Phillipa Burns Youssef Fady Matthew Simms Smith Nicholas 《Current Urology》2021,15(2):115
Background:Urosepsis is a recognized complication of transrectal ultrasound-guided prostate biopsy (TRUS-Bx). Pre-biopsy rectal swabs have been used to identify patients with microorganisms in the rectal flora resistant to the conventionally used empirical prophylaxis. The transperineal route of biopsy (TP-Bx) has a lower complication risk but comes at an increased cost.Materials and methods:Retrospective cohort study including patients undergoing prostate biopsies between October/2015 and April/2018. The intervention cohort, a rectal swab was performed, the result of which dictated the biopsy route; TRUS-Bx against TP-Bx. TP-Bx for patients with fluoroquinolone resistance or extended-spectrum β-lactamase. The control cohort underwent TRUS without a rectal swab receiving empirical antibiotics—oral ciprofloxacin and intravenous gentamicin.Results:Total 1000 patients were included in which 500 underwent a swab, 14 (2.8%) developed post-TRUS biopsy infective complications with 3 having positive bacteremia (0.6%); 500 had no swab, 47 (9.4%) developed post-TRUS biopsy infective complications with 22 (4.4%, p < 0.05) having positive bacteremia. Three patients (0.6%) of patients who underwent swab developed urinary tract infection symptoms whilst 12 (2.4%) had urinary tract infection in the control group. In those patients that underwent a swab, 14 required hospitalization with mean length of stay of 2.5 days versus 43 patients of the control with 3.6 days. Cost analysis concluded savings of this strategy was £18,711.Conclusions:We have demonstrated a protocol that reserves template biopsies for higher risk patients and can significantly reduce sepsis and other infectious complication rates whilst also proving to be a cost-efficient strategy. We recommend that units not utilizing rectal swabs to uncover the fluoroquinolone resistance rate by introducing them. We advocate units that already utilize rectal swabs, to introduce transperineal biopsy for their higher risk patients. 相似文献
999.
Archives of Sexual Behavior - 相似文献